Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: Going beyond associations

Breast Cancer Research

Volumn 12, Issue SUPPL. 4, 2010, Pages

  Ingle, James N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EXEMESTANE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; INTERLEUKIN 17; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER PATIENT; CASE CONTROL STUDY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL GENOMICS; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETICS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERLEUKIN-17; LINKAGE DISEQUILIBRIUM; MUSCULOSKELETAL DISEASES; NITRILES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIAZOLES;

EID: 78650917071     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2746     Document Type: Article

References (16)

1. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53. 10.1016/S1470-2045(07)70385-6, 18083636, The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group.
2. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret J-M, Pienkowski T, Wardely A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486-492. 10.1200/JCO.2006.08.8617, 17200148.
3. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJH, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lǿnning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, et al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570. 10.1016/S0140-6736(07)60200-1, 17307102.
4. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, . on behalf of the ABCSG and the GABG Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366:455-462. 10.1016/S0140-6736(05)67059-6, 16084253, on behalf of the ABCSG and the GABG.
5. Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006, 17(Suppl 7):vii10-4. 10.1093/annonc/mdl941, 16760270.
6. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study. J Clin Oncol 2007, 25:2664-2670. 10.1200/JCO.2006.08.8054, 17563395.
7. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu DS, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCICCTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271. 10.1093/jnci/dji250, 16145047.
8. Mamounas EP, Jeong J-H, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008, 26:1965-1971. 10.1200/JCO.2007.14.0228, 18332472.
9. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical Oncology clinical practice guidelines: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28:3784-3796. 10.1200/JCO.2009.26.3756, 20625130.
10. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008, 26:556-562. 10.1200/JCO.2007.11.5451, 18180462.
11. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007, 25:3877-3883. 10.1200/JCO.2007.10.7573, 17761973.
12. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 2010, 70:3278-3286. 10.1158/0008-5472.CAN-09-3024, 20354183.
13. Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman J-AW, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010, 28:4674-4682. 10.1200/JCO.2010.28.5064, 20876420.
14. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper cells. N Engl J Med 2009, 361:888-898. 10.1056/NEJMra0707449, 19710487.
15. Pearson TA, Manolio T. How to interpret a genome-wide association study. JAMA 2008, 299:1335-1344. 10.1001/jama.299.11.1335, 18349094.
16. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes D, Warren-Perry M, Tapper W, Eccles D, Evans DG, , Hooning M, Schutte M, van den Ouweland A, Houlston R, Ross G, Langford C, Pharoah PDP, Stratton MR, Dunning AM, Rahman N, Easton DF. The Breast Cancer Susceptibility Collaboration (UK) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010, 42:504-507. 10.1038/ng.586, 20453838, The Breast Cancer Susceptibility Collaboration (UK).